Kantify is a Brussels-based Frontier Lab using AI to discover new medicines against previously undruggable targets. The company was built on the conviction that patients with intractable targets deserve access to molecules that conventional methods cannot reach. Kantify's platform, Sapian, is an AI-native, orthogonal approach to drug discovery. It integrates target identification with non-structure-based small molecule design—pioneering a method that requires no experimental structural data and operates independently of traditional screening infrastructures. Sapian screens billions of compounds in silico, combining advanced multi-parameter optimization with proteome-wide selectivity.
| Website | http://www.kantify.com |
| Employees | 12 (7 on RocketReach) |
| Founded | 2017 |
| Phone | +32 484 91 42 17 |
| Technologies |
JavaScript
,
HTML
,
G Suite
+4 more
(view full list)
|
| Industry | Biotechnology Research, Artificial Intelligence, Big Data, Data and Analytics, Data Analytics, Science and Engineering, Retail Analytics, Software, Pricing, Consulting, FinTech, Financial Services, Machine Learning, Natural Language Processing, Predictive Analytics |
| Web Rank | 16 Million |
| Keywords | Ai Drug Discovery, Ai Healthcare Technology, Computational Drug Design, Precision Medicine Ai, Biotechnology Ai, Drug Discovery Platform, In Silico Drug Discovery, Therapeutic Ai, Innovative Drug Development |
| Competitors | Microsoft, IBM, Google, DataRobot, Dataiku, Alteryx, H2O.ai, Data Science Leaders Podcast, Zaloni, Altair RapidMiner +41 more (view full list) |
Looking for a particular Kantify employee's phone or email?
Segolene Martin is the CEO - Cofounder of Kantify.
7 people are employed at Kantify.